Moreover, the results provide a strong basis to consider CFTR potentiator treatment as a pharmacologic strategy to directly address acquired CFTR dysfunction in COPD using a treatment already available for CF. This evidence concerns the gene CFTR and chronic obstructive pulmonary disease.